Brief: Ocugen, Inc. Announces Signing Of Binding Term Sheet For The License Of Ocu400 Modifier Gene Therapy For Retinitis Pigmentosa In Korea
05/06/2025 12:22
Ocugen Inc OCGN.O: OCUGEN, INC. ANNOUNCES SIGNING OF BINDING TERM SHEET FOR THE LICENSE OF OCU400 MODIFIER GENE THERAPY FOR RETINITIS PIGMENTOSA IN KOREA OCUGEN INC - TO RECEIVE UP TO $11 MILLION IN UPFRONT FEES OCUGEN INC - SALES MILESTONES OF $150 MILLION OR MORE IN FIRST 10 YEARS OF COMMERCIALIZATION Source text: ID:nGNX4lxmzK Further company coverage: OCGN.O